Cara Therapeutics, Inc.
0HTC.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.11M
Close$
Share Statistics
| Market cap | $8.11 Million |
|---|---|
| Enterprise Value | $-7,509,447.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -366.69% |
|---|---|
| Return on Assets | -175.46% |
| Return on Invested Capital | -380.41% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.92 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cara Therapeutics Inc
12 employees
CEO: Derek Chalmers Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and...